Efficacy of Quinupristin-Dalfopristin against Methicillin-Resistant <i>Staphylococcus aureus</i> and Vancomycin-Insensitive <i>S. aureus</i> in a Model of Hematogenous Pulmonary Infection

Vol. 50, No. 5, 2004

Free Abstract Article (References) Article (PDF 246 KB)

Pharmacology

Efficacy of Quinupristin-Dalfopristin against Methicillin-Resistant Staphylococcus aureus and Vancomycin-Insensitive S. aureus in a Model of Hematogenous Pulmonary Infection
Katsunori Yanagihara^a,b, Makiko Okada^a,b, Yuichi Fukuda^a, Yoshifumi Imamura^a, Yukihiro Kaneko^a, Hideaki Ohno^a, Yasuhito Higashiyama^a, Yoshitsugu Miyazaki^a, Kazuhiro Tsukamoto^a,b, Yoichi Hirakata^a, Kazunori Tomono^a, Jun-Ichi Kadota^a, Takayoshi Tashiro^a, Ikuo Murata^a,b, Shigeru Kohno^a,c

^aSecond Department of Internal Medicine,
^bDepartment of Pharmacotherapeutics, Nagasaki University Graduate School of Pharmaceutical Sciences,
^cDivision of Molecular and Clinical Microbiology, Department of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Medical Sciences, Nagasaki, Japan

Address of Corresponding Author

Chemotherapy 2004;50:260-264 (DOI: 10.1159/000081948)

Key Words

Quinupristin-dalfopristin
Pulmonary infection
Methicillin-resistant Staphylococcus aureus
Vancomycin-insensitive Staphylococcus aureus

Abstract

Background: Quinupristin-dalfopristin (Q-D) is a mixture of quinupristin and dalfopristin, which are semisynthetic antibiotics of streptogramin groups B and A, respectively. Methods: We compared the effect of Q-D to that of vancomycin (VCM) in murine models of hematogenous pulmonary infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and VCM-insensitive S. aureus (VISA). Results: Treatment with Q-D resulted in a significant decrease in the number of viable bacteria in the lungs of mice in an MRSA infection model [Q-D 100 mg/kg, Q-D 10 mg/kg, VCM and control (mean ± SEM): 2.99 ± 0.44, 6.38 ± 0.32, 5.75 ± 0.43 and 8.40 ± 0.14 log₁₀ CFU/lung, respectively]. Compared with VCM, high-dose Q-D significantly reduced the number of bacteria detected in the VISA hematogenous infection model [Q-D 100 mg/kg, Q-D 10 mg/kg, VCM and control (mean ± SEM): 5.17 ± 0.52, 7.03 ± 0.11, 7.10 ± 0.49 and 7.18 ± 0.36 log₁₀ CFU/lung, respectively]. Histopathological examination confirmed the effect of Q-D. Conclusion: Our results suggest that Q-D is potent and effective in the treatment of MRSA and VISA hematogenous pulmonary infections.

Author Contacts

Katsunori Yanagihara, MD, PhD
Second Department of Internal Medicine, Nagasaki University School of Medicine
1-7-1 Sakamoto
Nagasaki, 852 (Japan)
Tel. +81 95 849 7276, Fax +81 95 849 7285, E-Mail kyana-ngs@umin.ac.jp

Article Information

Received: November 13, 2003
Accepted after revision: March 23, 2004
Published online: November 3, 2004
Number of Print Pages : 5
Number of Figures : 1, Number of Tables : 1, Number of References : 13

Medline Abstract (ID 15528893)

Download Citation

Cited In

For non-native English speakers and international authors who would like assistance with their writing before submission, we suggest American Journal Experts for their scientific editing service.